THERAVANCE BIOPHARMA, INC. (TBPH) Total liabilities 2016–2025
THERAVANCE BIOPHARMA, INC. (TBPH) total liabilities at each fiscal year-end, per SEC filings.
$188.8MFY2025 · since FY2016: $289.0M → $188.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $188.8M | +5.7% |
| FY2024 | $178.6M | +5.7% |
| FY2023 | $169.0M | +2.1% |
| FY2022 | $165.6M | -76.8% |
| FY2021 | $713.4M | -7.7% |
| FY2020 | $772.8M | +22.2% |
| FY2019 | $632.7M | +3.4% |
| FY2018 | $611.8M | +87.5% |
| FY2017 | $326.2M | +12.9% |
| FY2016 | $289.0M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice